Total Payments
$570,571
2024 Payments
$1,040
Companies
29
Transactions
709
Medicare Patients
2,758
Medicare Billing
$563,909
Payment Breakdown by Category
Other$279,625 (49.0%)
Consulting$182,525 (32.0%)
Travel$67,052 (11.8%)
Research$30,301 (5.3%)
Food & Beverage$11,067 (1.9%)
Education$0.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $268,263 | 147 | 47.0% |
| Consulting Fee | $182,525 | 28 | 32.0% |
| Travel and Lodging | $67,052 | 185 | 11.8% |
| Unspecified | $30,301 | 11 | 5.3% |
| Honoraria | $11,363 | 4 | 2.0% |
| Food and Beverage | $11,067 | 332 | 1.9% |
| Education | $0.50 | 2 | 0.0% |
Payments by Type
General
$540,270
698 transactions
Research
$30,301
11 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| UPSHER-SMITH LABORATORIES LLC | $233,952 | 163 | $0 (2023) |
| Amgen Inc. | $228,812 | 297 | $0 (2024) |
| Avanir Pharmaceuticals, Inc. | $32,877 | 55 | $0 (2019) |
| PFIZER INC. | $16,748 | 15 | $0 (2024) |
| Allergan, Inc. | $13,219 | 32 | $0 (2021) |
| Eli Lilly and Company | $12,378 | 3 | $0 (2021) |
| BioDelivery Sciences International, Inc. | $9,133 | 11 | $0 (2021) |
| Teva Pharmaceuticals USA, Inc. | $8,395 | 25 | $0 (2022) |
| Promius Pharma LLC | $4,905 | 10 | $0 (2019) |
| Lundbeck LLC | $3,002 | 13 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $1,040 | 20 | Tonix Medicines, Inc. ($667.22) |
| 2023 | $34,429 | 35 | UPSHER-SMITH LABORATORIES LLC ($17,466) |
| 2022 | $25,952 | 45 | UPSHER-SMITH LABORATORIES LLC ($25,560) |
| 2021 | $35,202 | 37 | Eli Lilly and Company ($9,843) |
| 2020 | $50,939 | 59 | Amgen Inc. ($25,990) |
| 2019 | $197,176 | 201 | Upsher-Smith Laboratories LLC ($98,979) |
| 2018 | $187,650 | 230 | Amgen Inc. ($97,185) |
| 2017 | $38,183 | 82 | Avanir Pharmaceuticals, Inc. ($27,215) |
All Payment Transactions
709 individual payment records from CMS Open Payments — Page 1 of 29
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/25/2024 | PFIZER INC. | ZAVZPRET (Drug) | Food and Beverage | In-kind items and services | $24.49 | General |
| Category: PAIN | ||||||
| 10/30/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: NEUROSCIENCE | ||||||
| 10/15/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $16.00 | General |
| Category: PAIN | ||||||
| 09/12/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $4.80 | General |
| Category: PAIN | ||||||
| 08/20/2024 | Lilly USA, LLC | EMGALITY (Drug) | Food and Beverage | In-kind items and services | $15.47 | General |
| Category: Neuroscience | ||||||
| 08/07/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $19.41 | General |
| Category: NEUROLOGY | ||||||
| 06/25/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $29.06 | General |
| Category: NEUROSCIENCE | ||||||
| 06/15/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $147.58 | General |
| Category: NEUROLOGY | ||||||
| 06/14/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Honoraria | Cash or cash equivalent | $500.00 | General |
| Category: NEUROLOGY | ||||||
| 06/03/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $29.32 | General |
| Category: NEUROLOGY | ||||||
| 05/20/2024 | Tonix Medicines, Inc. | ZEMBRACE SYMTOUCH (Drug) | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: NEUROLOGY | ||||||
| 05/14/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $18.05 | General |
| Category: PAIN | ||||||
| 05/09/2024 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $66.98 | General |
| Category: Neuroscience | ||||||
| 04/29/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: NEUROSCIENCE | ||||||
| 04/04/2024 | Amgen Inc. | Aimovig (Biological) | Food and Beverage | In-kind items and services | $22.64 | General |
| Category: Neuroscience | ||||||
| 03/13/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $16.01 | General |
| Category: NEUROSCIENCE | ||||||
| 02/14/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $21.44 | General |
| Category: NEUROLOGY | ||||||
| 02/08/2024 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $19.45 | General |
| Category: PAIN | ||||||
| 01/08/2024 | ABBVIE INC. | QULIPTA (Drug), UBRELVY | Food and Beverage | In-kind items and services | $19.64 | General |
| Category: NEUROSCIENCE | ||||||
| 01/03/2024 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $20.96 | General |
| Category: NEUROLOGY | ||||||
| 12/14/2023 | PFIZER INC. | ZAVZPRET (Drug) | — | Cash or cash equivalent | $2,687.94 | Research |
| Study: A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION • Category: PAIN | ||||||
| 12/04/2023 | PFIZER INC. | NURTEC ODT (Drug), ZAVZPRET | Food and Beverage | In-kind items and services | $3.02 | General |
| Category: PAIN | ||||||
| 11/18/2023 | TONIX PHARMACEUTICALS, INC. | ZEMBRACE SYMTOUCH (Drug), TOSYMRA | Food and Beverage | In-kind items and services | $134.86 | General |
| Category: NEUROLOGY | ||||||
| 11/17/2023 | Lundbeck LLC | VYEPTI (Biological) | Food and Beverage | Cash or cash equivalent | $23.59 | General |
| Category: NEUROLOGY | ||||||
| 10/24/2023 | Currax Pharmaceuticals LLC | ONZETRA XSAIL (Drug) | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION | PFIZER INC. | $14,057 | 4 |
| PREVENTIVE TREATMENT OF MIGRAINE: OUTCOMES FOR PATIENTS IN REAL-WORLD HEALTHCARE SYSTEMS (TRIUMPH) | Eli Lilly and Company | $9,843 | 1 |
| PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT OF MIGRAINE WITH OR WITHOUT AURA IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE | PFIZER INC. | $2,534 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE THE EVOLVE-1 STUDY | Eli Lilly and Company | $1,391 | 1 |
| A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY2951742 IN PATIENTS WITH EPISODIC MIGRAINE - THE EVOLVE-1 STUDY | Eli Lilly and Company | $1,144 | 1 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL EXTENSION STUDY TO EVALUATE THE LONG TERM SAFETY AND TOLOERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRANE WITH R WITHOUT AURA | Allergan Inc. | $976.00 | 2 |
| A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED SINGLE ATTACK STUDY TO EVALUATE THE EFFICACY, SAFETY AND TOLERABILITY OF ORAL UBROGEPANT IN THE ACUTE TREATMENT OF MIGRAINE | Allergan Inc. | $356.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 27 | 658 | 2,324 | $863,405 | $141,458 |
| 2022 | 27 | 732 | 2,378 | $864,796 | $139,601 |
| 2021 | 26 | 711 | 2,334 | $839,339 | $136,760 |
| 2020 | 13 | 657 | 2,534 | $970,452 | $146,090 |
Total Patients
2,758
Total Services
9,570
Medicare Billing
$563,909
Procedure Codes
93
All Medicare Procedures & Services
93 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 64417 | Injection of anesthetic agent and/or steroid into upper arm and shoulder nerve (axillary nerve) | Office | 2023 | 40 | 194 | $106,700 | $34,897 | 32.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 65 | 263 | $57,860 | $23,067 | 39.9% |
| 64415 | Injection of anesthetic agent and/or steroid into arm nerve bundle (brachial plexus) | Office | 2023 | 40 | 194 | $100,880 | $14,781 | 14.7% |
| 64461 | Injection of anesthetic agent into thoracic vertebra using imaging guidance, single site | Office | 2023 | 39 | 193 | $115,800 | $13,888 | 12.0% |
| 64400 | Injection of anesthetic agent and/or steroid into face nerve | Office | 2023 | 40 | 194 | $93,120 | $12,117 | 13.0% |
| 64418 | Injection of anesthetic agent and/or steroid into suprascapular shoulder nerve | Office | 2023 | 40 | 194 | $114,460 | $9,498 | 8.3% |
| 64450 | Injection of anesthetic agent and/or steroid into other nerve or branch | Office | 2023 | 41 | 214 | $94,160 | $9,024 | 9.6% |
| 64405 | Injection of anesthetic agent and/or steroid into upper neck and back of head nerve | Office | 2023 | 41 | 213 | $102,240 | $8,931 | 8.7% |
| 20553 | Injection of trigger points, 3 or more muscles | Office | 2023 | 39 | 193 | $29,336 | $4,443 | 15.1% |
| 95912 | Nerve conduction, 11-12 studies | Office | 2023 | 20 | 22 | $27,060 | $4,025 | 14.9% |
| 95886 | Needle measurement of electrical activity in arm or leg muscles, complete study | Office | 2023 | 20 | 44 | $12,320 | $3,218 | 26.1% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 16 | 16 | $6,720 | $2,522 | 37.5% |
| 80061 | Blood test, lipids (cholesterol and triglycerides) | Office | 2023 | 13 | 13 | $539.11 | $170.56 | 31.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 13 | 13 | $156.00 | $109.20 | 70.0% |
| 82977 | Glutamyltransferase (liver enzyme) level | Office | 2023 | 13 | 13 | $117.00 | $91.78 | 78.4% |
| 82150 | Amylase (enzyme) level | Office | 2023 | 13 | 13 | $117.00 | $82.55 | 70.6% |
| 84460 | Liver enzyme (sgpt), level | Office | 2023 | 13 | 13 | $212.81 | $67.47 | 31.7% |
| 84450 | Liver enzyme (sgot), level | Office | 2023 | 13 | 13 | $208.26 | $66.04 | 31.7% |
| 82247 | Bilirubin level, total | Office | 2023 | 13 | 13 | $91.00 | $63.96 | 70.3% |
| 84075 | Phosphatase (enzyme) level, alkaline | Office | 2023 | 12 | 12 | $84.00 | $60.96 | 72.6% |
| 82310 | Calcium level, total | Office | 2023 | 12 | 12 | $84.00 | $60.72 | 72.3% |
| 82040 | Albumin (protein) level | Office | 2023 | 12 | 12 | $84.00 | $58.20 | 69.3% |
| 85651 | Red blood cell sedimentation rate, to detect inflammation, non-automated | Office | 2023 | 13 | 13 | $195.00 | $54.34 | 27.9% |
| 82947 | Blood glucose (sugar) level | Office | 2023 | 13 | 13 | $78.00 | $50.05 | 64.2% |
| 84520 | Urea nitrogen level to assess kidney function, quantitative | Office | 2023 | 12 | 12 | $72.00 | $46.44 | 64.5% |
About Dr. Marshall Freeman, MD
Dr. Marshall Freeman, MD is a Specialist healthcare provider based in Greensboro, North Carolina. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/26/2006. The National Provider Identifier (NPI) number assigned to this provider is 1710944756.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marshall Freeman, MD has received a total of $570,571 in payments from pharmaceutical and medical device companies, with $1,040 received in 2024. These payments were reported across 709 transactions from 29 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($268,263).
As a Medicare-enrolled provider, Freeman has provided services to 2,758 Medicare beneficiaries, totaling 9,570 services with total Medicare billing of $563,909. Data is available for 4 years (2020–2023), covering 93 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Neurology
- Location Greensboro, NC
- Active Since 04/26/2006
- Last Updated 07/16/2013
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1710944756
Products in Payments
- Aimovig (Biological) $210,564
- QUDEXY XR Topiramate Extended Release Capsules (Drug) $170,478
- ONZETRA Xsail (Drug) $32,087
- TOSYMRA (Drug) $26,048
- ZEMBRACE SYMTOUCH (Drug) $23,459
- ZAVZPRET (Drug) $14,081
- UBRELVY (Drug) $13,472
- ELYXYB - CELECOXIB (Drug) $9,133
- TOSYMRA SUMATRIPTAN NASAL SPRAY (Drug) $7,916
- Zembrace (Drug) $4,889
- AJOVY (Drug) $4,427
- NURTEC ODT (Drug) $3,201
- VYEPTI (Biological) $3,002
- MIGRANAL (Drug) $2,784
- NUEDEXTA (Drug) $770.00
- BOTOX (Drug) $375.00
- Tosymra Sumatriptan Nasal Spray (Drug) $179.80
- ZOMIG (Drug) $134.47
- AIMOVIG (Biological) $131.33
- EMGALITY (Drug) $125.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Greensboro
Randy Kritzer, M.d, M.D
Specialist — Payments: $158,350
Specialist $158,350
Dr. Frank Aluisio, Md, MD
Specialist — Payments: $19,376
Specialist $19,376
Dr. Howard Holderness, M.d, M.D
Specialist — Payments: $12,101
Specialist $12,101
Dr. Kevin Supple, Md, MD
Specialist — Payments: $10,310
Specialist $10,310
Dr. Donald Digby, M.d, M.D
Specialist — Payments: $5,760
Specialist $5,760
Dr. Jason Sanders, M.d, M.D
Specialist — Payments: $4,270
Specialist $4,270